This site is intended for health professionals only

Published on 12 May 2009

Share this story:
Twitter
LinkedIn

Green light for dissolvable Lamictal

teaser

A dissolvable version of GlaxoSmithKline’s drug Lamictal has been approved by the US Food and Drug Administration (FDA).

The breakthrough will allow patients who have difficulty swallowing tablets to take the drug by letting it disintegrate on their tongue.

Lamictal, or lamotrigine, is used to treat epilepsy or bipolar disorders by either stabilising seizures or moods.

A statement from the company said the FDA has approved dissolvable Lamictal ODT in 25mg, 50 mg, 100 mg and 200 mg strengths and it is expected to be available by July.

The patent on Lamictal expired last year and since then other pharmaceutical companies have produced generic versions of the drug, with global sales in 2008 totalling $1.7 billion (£1.2bn). This has had a negative impact on GlaxoSmithKline’s profits.

Copyright Press Association 2009

GlaxoSmithKline



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn